140 related articles for article (PubMed ID: 8562942)
21. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
[TBL] [Abstract][Full Text] [Related]
22. [Involvement of WT1 gene expression in regulation of P53 and MDM2 proteins function in acute lymphoblastic leukemia].
Bartkowiak J; Wójcik I; Stankiewicz W
Pol Merkur Lekarski; 2001 Nov; 11(65):402-5. PubMed ID: 11852808
[TBL] [Abstract][Full Text] [Related]
23. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
24. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
25. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
26. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Sourvinos G; Spandidos DA
Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
28. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
29. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
30. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Nov; 94(5):593-600. PubMed ID: 12424454
[TBL] [Abstract][Full Text] [Related]
31. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
Jiang M; Shao ZM; Wu J; Lu JS; Yu LM; Yuan JD; Han QX; Shen ZZ; Fontana JA
Int J Cancer; 1997 Oct; 74(5):529-34. PubMed ID: 9355976
[TBL] [Abstract][Full Text] [Related]
32. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
34. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
36. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
37. [Study on MDM2 and p53 gene proteins expression on acute leukemic cells and its correlation with chemotherapeutic efficacy].
Lin M; Liu Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):350-2. PubMed ID: 11189516
[TBL] [Abstract][Full Text] [Related]
38. The p53 and mdm-2 genes in human testicular germ-cell tumors.
Riou G; Barrois M; Prost S; Terrier MJ; Theodore C; Levine AJ
Mol Carcinog; 1995 Mar; 12(3):124-31. PubMed ID: 7893365
[TBL] [Abstract][Full Text] [Related]
39. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
